More than six years of follow-up data show that Opdivo alone, or in combination with Yervoy, continued to induce long-term survival benefits compared to Yervoy alone in patients with previously ...

Previously, treatments for patients with extensive-disease small cell lung cancer were limited with a poor prognosis. Researchers sought to investigate if Opdivo plus Yervoy or Opdivo alone would ...

Opdivo is a programmed death receptor-1 (PD-1) blocking antibody. The Food and Drug Administration (FDA) has expanded the approval of Opdivo ® (nivolumab) to include adjuvant treatment of patients 12 ...

The FDA nod for Bristol Myers Squibb’s Opdivo for treating early-stage non-small cell lung cancer (NSCLC) before surgery came so quickly in March, the company had yet to publicize results from an ...

Swallowable sampling device combined with methylation biomarker panel IDs Barrett esophagus. The approvals are based on data from the phase 3 CheckMate-648 trial, which included 970 adults with ...

The U.S. Food and Drug Administration (FDA) on Tuesday approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment of adult and pediatric ...

Yesterday, drug manufacturer Bristol-Myers Squibb announced that the FDA has approved the combination nivolumab (Opdivo) plus low-dose ipilimumab (Yervoy) for the treatment of adult and pediatric ...

If you are wondering whether Bristol-Myers Squibb is priced attractively right now, you are not alone. This article walks ...

Doctors may recommend nivolumab (Opdivo) adjuvant for some people with bladder cancer. This includes those with a high risk of recurrence following bladder surgery and people who have received ...